Consolidation Treatment and Long-Term Prognosis of Rituximab in Minimal Change Disease and Focal Segmental Glomerular Sclerosis

PURPOSE: There is currently a lack of studies investigating long-term prognosis and the necessity of further rituximab (RTX) consolidation treatment for minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS). The aim of this study was to evaluate the efficacy of RTX for these dis...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Drug Des Devel Ther
Autori principali: Lin, Li, Wang, Weiming, Wu, YiFan, Xie, JingYuan, Li, Xiao, Pan, XiaoXia, Zhang, Wen, Xu, Jing, Cai, YiKai, Ren, Hong, Chen, Nan
Natura: Artigo
Lingua:Inglês
Pubblicazione: Dove 2021
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8121273/
https://ncbi.nlm.nih.gov/pubmed/34007154
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S302257
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi